NEW YORK CITY -- Global pharmaceutical giant Pfizer Inc. (Nadaq: PFE) has again delayed the release of its new cancer curing drug, "Curacea."
    Pfizer has made a full turnaround in recent years with runaway drug successes like pink oval-shaped Zoloft and blue Viagra parralellograms. VP John Niblack said the delay was because of techinical reasons. "We just can't decide on the color of the new buggers," he elaborated. "Do you like Iridium Blue or Savage Yellow? We're having a hung jury on this one."
    Insiders say there is also a holdup in the marketing department on a decision on the slogan of the new drug. "Cancer: what is it good for?" and "Be cancer-free with Curacea! Now with 50% more riboflavin!" are reported candidates.
    Despite the delays most analysts expect the drug to ship in as early as four weeks. "They're smart enough not to let this delay affect their bottom line," said one industry expert.
    Cancer is a widespread illness which kills 6,000 people a week.